The International Neuromodulation Society

The Fastest-Growing, Worldwide Multidisciplinary Body Devoted to Building Knowledge of Neuromodulation

The International Neuromodulation Society (INS) is a non-profit group of clinicians, scientists and engineers dedicated to the scientific development and awareness of neuromodulation – the alteration of nerve activity through targeted delivery of a stimulus, such as electrical stimulation or chemical agents, to specific neurological sites in the body. The San Francisco-based INS was formed in 1989 and educates and promotes the field through meetings, its peer-reviewed journal Neuromodulation: Technology at the Neural Interface, explanatory content, and chapter websites. The INS also provides information for patients and produces rolling news briefs about this rapidly evolving field.

The INS Peer-Reviewed Journal – 8 Issues a Year

The INS journal Neuromodulation: Technology at the Neural Interface has a growing Impact Factor and is indexed in Index Medicus, MEDLINE and Pubmed from its first issue in 1998. Members may log in to the members-only section to read the journal online.

journal cover

+Submit a Manuscript.+


What is Neuromodulation?

Medical Professionals can learn about various considerations concerning neuromodulation and clinic contacts. Once your preliminary questions have been answered, please use the Contact Us facility to find out more and to discuss specific objectives. Others may simply wish to join the INS and one of its related chapter societies, please use the Membership Application.

Clinical trials that involve a wide range of emerging neuromodulation approaches are listed on our Research page. Neuromodulation clinical trials address symptom control through nerve stimulation in such condition categories as:

If you are not a medical professional and you are searching for information about neuromodulation and how these types of treatment could benefit a specific condition such as treatment-resistant headache or other chronic pain syndromes, you may find the sections titled Therapies, About Neuromodulation or FAQs particularly helpful.

Members may log in and visit the members-only section’s Global Discussion Forum

Breaking News Share

Neurostimulation Company Releases Six-Month Study Data

Jan. 17, 2019 - Stimwave released six-month data from a trial of its spinal cord stimulation system in patients with back and leg pain, in which high or low frequency stimulation was used. (Mass Device)

First Patient Enrolled in Study of Intrathecal Drug Delivery in Pain Patients Who Were Weaned Off of Oral Opioids

Jan. 17, 2019 - Medtronic announced enrollment of the first patient in a study of the use of its intrathecal drug delivery device in people with chronic intractable non-malignant primary back pain who have been weaned off of oral opioids. (Drug Delivery Business News)

Annual Research Prize for Junior Investigators Announced

Jan. 16, 2019 - There is a March 15, 2019 deadline for junior investigators aged 45 or younger, who have received an advanced degree in the past 10 years, to submit an entry for the Science and PINS Prize in Neuromodulation. The $25,000 prize is based on an essay about research performed in the past three years. The award was started in 2016 by Science magazine and PINS Medical of China. In addition to the cash award, winners have their essay published in Science magazine. (Science 2.0)

Israeli Company Prepares for US. Stock Exchange Offering

Jan. 15, 2019 - Brainsway Ltd. has filed a prospectus for a public offering on Nasdaq to raise at least $30 million. Timing of the offering depends upon when approval of the prospectus is received from the U.S. Securities and Exchange Commission, which was affected by the U.S. government shutdown. (Globes)

Industry Observers Discuss the Role of Neuromodulation in Pain Treatment

Jan. 15, 2019 - A news feature about neuromodulation and pain presents viewpoints about a larger context for the treatment, with one physician saying neuromodulation can be part of the answer to part of the opioid problem, and that with individual patients, expectation management is important. (Mass Device)


To see select neuromodulation news by category, as well as news about the INS in particular, please visit the Newsroom. To see archived news briefs dating back to January 2011, visit the News Archive.

Continue Reading News Briefs
Last Updated on Monday, December 12, 2016 10:01 AM